Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.7.0.1
Licenses Acquired - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 03, 2017
May 31, 2017
Apr. 25, 2017
Mar. 31, 2017
Feb. 17, 2017
Jan. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research And Development In Process                 $ 1,800,000 $ 2,060,000 $ 3,094,000 $ 2,143,000
City Of Hope [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments for Fees         $ 100,000              
Revenue Recognition Milestone Method Payments Due         100,000              
Effcon Laboratories, Inc [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research And Development In Process                 300,000      
Payment of Upfront Fees             $ 200,000          
Revenue Recognition Milestone Method Payments Due               $ 2,300,000        
Royalty Guarantees, Commitments, Amount               $ 1,600,000        
Jubilant Biosys Ltd [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research And Development In Process       $ 400,000                
Royalty Revenue                 $ 100,000 1,000,000 $ 600,000 1,000,000
National Institute of Child Health and Human Development [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payment of Upfront Milestone Fees       $ 100,000                
Columbia University [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Stock Issued During Period, Shares, Purchase of Assets           1,050,000            
Shares Issued, Price Per Share                 $ 0.028   $ 0.028  
Stock Issued During Period, Value, Purchase of Assets                     $ 29,000  
Payment of Upfront Milestone Fees           $ 200,000            
Revenue Recognition Milestone Method Payments Due           $ 5,500,000            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners           10.00%            
Collaborative Agreements with TGTX [Member] | NeuPharma [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments for Fees                 $ 9,000 3,000 38,000 20,000
Checkpoint Therapeutics, Inc [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research And Development In Process                 $ 0 $ 2,060,000 400,000 $ 2,060,000
Payment of Upfront Fees                     $ 2,000,000  
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners [1],[2]                 62.40% 64.30% 62.40% 64.30%
Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Stock Issued During Period, Value, Purchase of Assets                 $ 1,800,000   $ 3,100,000  
UCLA License [Member] | University of California [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payment of Upfront Fees     $ 200,000                  
A&R CD123 License [Member] | City Of Hope [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition Milestone Method Payments Due         14,500,000              
A&R IL-13 License [Member] | City Of Hope [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research And Development In Process                     $ 300,000  
Revenue Recognition Milestone Method Payments Due         $ 14,500,000              
CS1 Technology License [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition Milestone Method Payments Due   $ 14,900,000                    
Annual Maintenance Fee Payable   50,000                    
CS1 Technology License [Member] | Subsequent Event [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payment of Upfront Fees $ 600,000                      
PSCA Technology License [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition Milestone Method Payments Due   14,900,000                    
Annual Maintenance Fee Payable   50,000                    
PSCA Technology License [Member] | Subsequent Event [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payment of Upfront Fees 300,000                      
HER2 Technology License [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition Milestone Method Payments Due   14,900,000                    
Annual Maintenance Fee Payable   $ 50,000                    
HER2 Technology License [Member] | Subsequent Event [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payment of Upfront Fees $ 600,000                      
[1] Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.
[2] Represents a weighted average of ownership during the periods presented.